Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar 24;4(6):1094-1101.
doi: 10.1182/bloodadvances.2019001335.

The prognostic impact of FLT3-ITD and NPM1 mutation in adult AML is age-dependent in the population-based setting

Gunnar Juliusson  1   2 , Martin Jädersten  3 , Stefan Deneberg  3 , Sören Lehmann  3   4 , Lars Möllgård  5 , Lovisa Wennström  5 , Petar Antunovic  6 , Jörg Cammenga  6 , Fryderyk Lorenz  7 , Emma Ölander  8 , Vladimir Lj Lazarevic  1   2 , Martin Höglund  4
Affiliations

The prognostic impact of FLT3-ITD and NPM1 mutation in adult AML is age-dependent in the population-based setting

Gunnar Juliusson et al. Blood Adv. .

Abstract

In acute myeloid leukemia (AML) FLT3 internal tandem duplication (ITD) and nucleophosmin 1 (NPM1) mutations provide prognostic information with clinical relevance through choice of treatment, but the effect of age and sex on these molecular markers has not been evaluated. The Swedish AML Registry contains data on FLT3-ITD and NPM1 mutations dating to 2007, and 1570 adult patients younger than 75 years, excluding acute promyelocytic leukemia, had molecular results reported. Females more often had FLT3ITD and/or NPM1mut (FLT3ITD: female, 29%; male, 22% [P = .0015]; NPM1mut: female, 36%; male, 27% [P = .0001]), and more males were double negative (female, 53%; male, 64%; P < .0001). Patients with FLT3ITD were younger than those without (59 vs 62 years; P = .023), in contrast to patients with NPM1mut (62 vs 60 years; P = .059). Interestingly, their prognostic effect had a strong dependence on age: FLT3ITD indicated poor survival in younger patients (<60 years; P = .00003), but had no effect in older patients (60-74 years; P = .5), whereas NPM1mut indicated better survival in older patients (P = .00002), but not in younger patients (P = .95). In FLT3ITD/NPM1mut patients, the survival was less dependent on age than in the other molecular subsets. These findings are likely to have clinical relevance for risk grouping, study design, and choice of therapy.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Figures

None
Graphical abstract
Figure 1.
Figure 1.
OS by FLT3-ITD and age. (Left) Aged younger than 60 years (P = .00003). (Right) Aged 60 to 74 years (P = .5).
Figure 2.
Figure 2.
OS by NPM1 mutation and age. (Left) Aged younger than 60 years (P = .95). (Right) Aged 60 to 74 years (P = .00002).
Figure 3.
Figure 3.
OS by FLT3-ITD, NPM1 mutation, and age. (Left) Aged younger than 60 years. (Right) Aged 60 to 74 years. Log rank analyses of survival in patients younger than 60 years (left): comparison of all 4 subsets (P = .00027); no FLT3-ITD/NPM1 mutated (group A) vs double-negative (group B; P = .049); FLT3-ITD/NPM1 mutated (group C) vs FLT3-ITD/NPM1 wild type (group D; P = .62); group A vs C (P = .0005); group A vs D (P = .0004); group B vs C (P = .007); group B vs D (P = .018). Patients aged 60 to 74 years (right): all 4 subsets (P < .0001, group A vs B (P < .0001), group C vs D (P = .049), group A vs C (P = .073), group A vs D (P < .0001), group B vs C (P = .10), and group B vs D (P = .37).
See this image and copyright information in PMC

References

    1. Abelson S, Collord G, Ng SWK, et al. . Prediction of acute myeloid leukaemia risk in healthy individuals. Nature. 2018;559(7714):400-404. - PMC - PubMed
    1. Bullinger L, Döhner K, Döhner H. Genomics of acute myeloid leukemia diagnosis and pathways. J Clin Oncol. 2017;35(9):934-946. - PubMed
    1. Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136-1152. - PubMed
    1. Grimwade D, Walker H, Oliver F, et al. ; The Medical Research Council Adult and Children’s Leukaemia Working Parties . The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood. 1998;92(7):2322-2333. - PubMed
    1. Kottaridis PD, Gale RE, Frew ME, et al. . The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001;98(6):1752-1759. - PubMed

Publication types